Abstract | BACKGROUND: METHODS: RESULTS: Following bolus injection, free and total phenoxodiol appeared to follow first order pharmacokinetics. The elimination half-lives for free and total phenoxodiol were 0.67 ± 0.53 h and 3.19 ± 1.93 h, respectively, while the total plasma clearance rates were 2.48 ± 2.33 L/h and 0.15 ± 0.08 L/h, respectively. The respective apparent volumes of distribution were 1.55 ± 0.69 L/kg and 0.64 ± 0.51 L/kg. During continuous intravenous infusion, free phenoxodiol accumulated rapidly to reach a mean concentration at steady state of 0.79 ± 0.14 μg/ml after 0.87 ± 0.18 h. The apparent accumulation half-life of free phenoxodiol was 0.17 ± 0.04 h while the plasma clearance during continuous infusion was 1.29 ± 0.23 L/h. CONCLUSIONS:
Phenoxodiol has a short plasma half-life, particularly in the free form, leading to a rapid attainment of steady state levels during continuous intravenous infusion. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12610000334000.
|
Authors | Jan B Howes, Paul L de Souza, Leanne West, Li Jiu Huang, Laurence G Howes |
Journal | BMC clinical pharmacology
(BMC Clin Pharmacol)
Vol. 11
Pg. 1
(Feb 03 2011)
ISSN: 1472-6904 [Electronic] England |
PMID | 21291562
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adolescent
- Adult
- Aged
- Australia
- Breast Neoplasms
(drug therapy, metabolism)
- Female
- Half-Life
- Humans
- Infusions, Intravenous
- Isoflavones
(administration & dosage, adverse effects, pharmacokinetics)
- Male
- Middle Aged
- New Zealand
- Prostatic Neoplasms
(drug therapy, metabolism)
- Young Adult
|